Pharma BD Deal Intelligence

Bristol-Myers Squibb Company / Padlock Therapeutics, Inc.

2016 · Acquisition/Merger · $600M · Complete

Announcement Sentiment

Strongly positive

BMS acquired Cambridge, MA-based Padlock Therapeutics for up to $600M (upfront cash plus development milestones tied to advancement of PAD inhibitor program for rheumatoid arthritis and other autoimmune diseases). Acquisition gave BMS full rights to Padlock's PAD discovery program. Closed Q2 2016.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Pipeline outcome

Assets Stalled

Assessment window: 10yr post-close.

Key facts

Announced Mar 03, 2016
Closed Apr 04, 2016
Deal value $600M
Deal type Acquisition/Merger
Therapeutic area Rheumatoid arthritis, systemic lupus erythematosus, other autoimmune diseases
Indications Rheumatoid arthritis, systemic lupus erythematosus, other autoimmune diseases
Key assets Protein/Peptidyl Arginine Deiminase (PAD) inhibitor discovery program
Mechanism Small molecule PAD enzyme inhibitors

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals